SCIESCOPUSQ2
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
MARY ANN LIEBERT, INC, United States
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS is an academic journal published by MARY ANN LIEBERT, INC (United States). Identifiers: ISSN 1084-9785, eISSN 1557-8852. Indexed in SCIE, SCOPUS. Metrics: JIF 2.1, CiteScore 7.1, SJR 0.550, SNIP 0.57. Subject areas: MEDICINE, NUCLEAR MEDICINE & MEDICAL IMAGING, ONCOLOGY, PHARMACOLOGY & PHARMACY. tlooto lists 2,587 papers from this journal.
CiteScore
7.10
Scopus citation metric
SJR
0.550
SCImago rank
SNIP
0.57
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- 1084-9785
- eISSN
- 1557-8852
- Abbreviation
- CANCER BIOTHER RADIO
- Publisher
- MARY ANN LIEBERT, INC
- Country
- United States
Web of Science categories
SCIEMEDICINE, NUCLEAR MEDICINE & MEDICAL IMAGING, ONCOLOGY, PHARMACOLOGY & PHARMACY, RADIOLOGY, RESEARCH & EXPERIMENTAL
Scopus ASJC categories
1306 Cancer Research2730 Oncology2741 Radiology3004 Pharmacology
Keywords
Oncology | Medicine, Research & Experimental | Pharmacology & Pharmacy | Radiology, Nuclear Medicine & Medical Imaging
Papers in this journal
Recent papers
- On the Importance of Extracting the Needle from the Haystack.
2026
- Radionuclide Therapy Integrated Multimodal Transsylvian Microneurosurgical Management of Type 5 Insular and Paralimbic Gliomas for Precision Oncology.
2026
- A New Chapter in Radiopharmaceutical Science
2026
- Lactylation Signatures as Predictors of Prognosis and Therapeutic Response in Lung Adenocarcinoma: Implications for Ultrasound-Based Therapeutic Strategies
2026
- Melatonin as an Epigenetic Modulator to Regulate Angiogenesis in Dalton's Lymphoma.
2026
Most cited papers
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs
1997 · 424 citations
- Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research
2009 · 367 citations
- Growing applications of “click chemistry” for bioconjugation in contemporary biomedical research
2009 · 292 citations
- Affinity and Avidity in Antibody-Based Tumor Targeting
2009 · 231 citations
- A Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α v β 3) Antibody in Patients with Metastatic Cancer
2001 · 215 citations